SCHEMBL2075233

SCHEMBL2075233

COc1cc([N+](=O)[O-])ccc1C#CCN1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
HTT P42858 2/20 0.49
TDP1 Q9NUW8 3/20 0.45
LMNA P02545 5/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
GFER P55789 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MAPK1 P28482 2/20 0.41
DRD4 P21917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6300165 0.78 HTT (0.55) ALDH1A1HTTTDP1LMNAMAPT
SCHEMBL311004 0.76 ALDH1A1 (0.54) ALDH1A1HTTTDP1LMNAMAPT
SCHEMBL7345284 0.76 KCNJ1 (0.59) ALDH1A1HTTTDP1MEN1PKM
SCHEMBL6791413 0.75 HTT (0.51) ALDH1A1HTTTDP1LMNAMAPT
SCHEMBL9127112 0.74 HTT (0.61) ALDH1A1HTTTDP1LMNAMAPT
SCHEMBL3171647 0.74 KCNJ1 (0.58) ALDH1A1HTTTDP1MEN1PKM
SCHEMBL5388591 0.74 ALDH1A1 (0.54) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL1929880 0.72 LTA4H (0.57) ALDH1A1TDP1LMNAMAPTMEN1
SCHEMBL264564 0.72 LTA4H (0.57) ALDH1A1TDP1LMNAMAPTMEN1
SCHEMBL7238168 0.72 HTT (0.62) ALDH1A1HTTTDP1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
EP-1828207-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066174-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R ALDH1A1 668/4885HTT 181/4885TDP1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.